awgldk
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Triples
Insights
Schema
BETA
Class frequency
Class hierarchy
SPARQL
GraphQL
BETA
Graphs
1
Q28076490-F992C341-5620-4925-82D6-8483A59405A8
Q28076490-F992C341-5620-4925-82D6-8483A59405A8
BestRank
Statement
http://www.wikidata.org/entity/statement/Q28076490-F992C341-5620-4925-82D6-8483A59405A8
Mechanisms of resistance to anti-epidermal growth factor receptor inhibitors in metastatic colorectal cancer
P2860
Q28076490-F992C341-5620-4925-82D6-8483A59405A8
BestRank
Statement
http://www.wikidata.org/entity/statement/Q28076490-F992C341-5620-4925-82D6-8483A59405A8
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
2b4d74d478775043ef6ce3e65e4a615f666194f4
P2860
PEAK: a randomized, multicenter phase II study of panitumumab plus modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) or bevacizumab plus mFOLFOX6 in patients with previously untreated, unresectable, wild-type KRAS exon 2 metastatic color